A variety of evidence suggest that the metabolic outcomes associated with CDK4/6 inhibition are context specific and CDK4/6 inhibitors may have different and even opposing effects on energy metabolism in different cancers or in the same cancer type depending on the conditions (15). Here, CDK4 is linked to cancer.